Inventiva S.A IVA 深 滬
已收盤 12-05 16:00:00 美东时间
4.13
-0.050
-1.20%
華盛通- 最 高4.21
- 今 開4.18
- 成交量 14.80万股
- 最 低 4.05
- 昨 收 4.18
- 總市值 5.74亿
- 52周最高 7.9825
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 2.1112
- 委 比 43.50%
- 總股本 1.39亿
- 歷史最高 19.064
- 量 比 0.75
- 振 幅 3.83%
- 歷史最低 1.53
- 每 手 1
- 風險率 1.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Shares of LexinFintech Holdings Ltd – ADR (NASDAQ:LX) rose sharply in pre-marke...
11-24 18:23
Inventiva S.A reports 9M results
Inventiva S.A (IVA): Revenues for the first nine months of 2025 amounted to €4.5 million, compared to none generated for the same period in 2024. Cash and cash equivalents at €97.6 million, and €24.7 ...
11-22 05:05
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
Guggenheim Maintains Buy on Inventiva, Lowers Price Target to $11
Guggenheim analyst Seamus Fernandez maintains Inventiva (NASDAQ:IVA) with a Buy and lowers the price target from $13 to $11.
11-18 22:16
Inventiva Secures $172.5M from Full Exercise of Underwriters’ Option
Inventiva ( ($IVA) ) just unveiled an update. On November 17, 2025, Inventiva a...
11-17 19:29
Inventiva Prices U.S. Offering Of 38.96M ADSs At $3.85 Each; Settlement Expected November 17
Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated
11-13 22:24
Inventiva announces $125M U.S. public offering of ADSs
Inventiva (IVA) plans to offer ~$125 American Depositary Shares. Each ADS will represent one new ordinary share of the company. The underwritten public offering will be conducted in the United States ...
11-13 05:42
Inventiva Plans To Launch $125M American Depositary Shares Offering
Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated
11-13 05:37
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Wolfe Research Initiates Coverage On Inventiva with Outperform Rating, Announces Price Target of $13
Wolfe Research analyst Steve Fleishman initiates coverage on Inventiva (NASDAQ:IVA) with a Outperform rating and announces Price Target of $13.
11-06 21:24
